Physician profile
James E Kuneman
NPI 1699769521
$1,540.41
in general payments reported to CMS, 2019-2025
14 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $77.07 · 2021: $99.03 · 2022: $360 · 2023: $227 · 2024: $313 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.64 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $210.57 | 2022-2025 | Infuse, Vyzulta |
| Biotissue Holdings INC. | $193.85 | 2022-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $177.60 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $126.45 | 2021-2025 | Acthar |
| Alcon Vision LLC | $93.25 | 2021-2025 | Argos, Clareon, Rocklatan |
| Tarsus Pharmaceuticals, INC. | $65.14 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $62.39 | 2022-2025 | Acuvue |
| Oyster Point Pharma, INC. | $59.66 | 2023-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $55.69 | 2019-2021 | |
| Allergan, INC. | $31.24 | 2022 | |
| Horizon Therapeutics Plc | $22.11 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Aerie Pharmaceuticals, INC. | $18.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kuneman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.